Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First exposure to SARS-CoV-2 shapes IgG subclass switching after mRNA vaccination.

Communications medicine·2026

Same author

CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review.

American journal of clinical pathology·2026

Same author

Increased CD103+ T lymphocytes in lymph nodes as a marker of metastasis from non-haematopoietic malignancies.

Journal of clinical pathology·2026

Same author

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19.

International journal of laboratory hematology·2026

Same author

Islet-derived T cells from both mice and humans recognize conserved insulin A-chain peptides presented by HLA-C*03:04.

Journal of immunology (Baltimore, Md. : 1950)·2026

Same author

Neutrophil-derived reactive oxygen species mediate doxorubicin-induced cardiotoxicity and skeletal myopathy.

American journal of physiology. Heart and circulatory physiology·2026

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

CD8+ T cells in type 1 diabetes.

Sue Tsai¹, Afshin Shameli, Pere Santamaria

¹Julia McFarlane Diabetes Research Centre (JMDRC), Department of Microbiology and Infectious Diseases, Canada.

Advances in Immunology

|December 30, 2008

Summary

This summary is machine-generated.

Autoreactive CD8+ T cells are key drivers of pancreatic beta cell destruction in type 1 diabetes (T1D). Research is advancing understanding of these cells to develop targeted immunotherapies for T1D.

More Related Videos

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Experiment Videos

Last Updated: Jun 26, 2026

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Area of Science:

Immunology
Endocrinology
Autoimmunity

Background:

Type 1 diabetes (T1D) was previously thought to be solely mediated by CD4+ T cells.
Emerging evidence highlights a critical role for autoreactive CD8+ T cells in T1D pathogenesis.
CD8+ T cells are implicated in pancreatic beta cell destruction and sustained islet inflammation, particularly in the nonobese diabetic (NOD) mouse model.

Purpose of the Study:

To review recent advances in understanding the role of CD8+ T cells in T1D.
To discuss mechanisms of CD8+ T cell activation, homing, and beta cell destruction.
To explore the development of novel immunotherapies targeting CD8+ T cells for T1D treatment.

Main Methods:

Review of current scientific literature on CD8+ T cells in T1D.
Analysis of findings from the nonobese diabetic (NOD) mouse model.
Examination of human studies involving genetic linkage, epitope identification, and patient blood sample analysis.

Main Results:

CD8+ T effector cells are central to beta cell destruction and islet inflammation in T1D.
Mechanisms of CD8+ T cell activation, migration to islets, and cytotoxic function are being elucidated.
Human studies increasingly support the significant involvement of CD8+ T cells in T1D.

Conclusions:

Understanding CD8+ T cell roles in T1D is crucial for developing effective treatments.
Targeting autoreactive CD8+ T cells offers a promising strategy for antigen-specific immunotherapy in T1D.
Converging research in mouse models and human studies paves the way for novel T1D immunotherapies.